Yi Shi Email & Phone Number

上海市

Key responsibilities:1. Responsible for the construction and operation of the mRNA display platform, using mRNA display technology to screen antibodies/peptides.2. Lead the team to conduct target investigation, antibody design (monoclonal antibodies and bi-specifics,), lead optimization (affinity maturation, Fc engineering for effector function and half-life etc) and in vitro activity determination until PCC confirmation.3. Responsible for organizing/participating in the theoretical and experimental verification of new drug targets and new therapeutic techniques.4. Responsible for organizing the processing and analysis of experimental data and writing experimental summary reports, papers, and patents.5. Responsible for the overall operation of the project, the determination of outsourcing partners, project progress follow-up, project acceptance audit, etc., and coordinating the cooperation with other departments within the company.6. Responsible for team building, guiding, and training new colleagues on experimental methods and skills.

Key responsibilities: Lead a group to perform protein drug R&D and structure-based drug discovery. Supervise the postgraduate students Apply for R&D fundingAchievement: Structural studies and drug discovery of PRC2 complex Structure-based design of a hyper-thermostable Uricase for hyperuricemia and gout therapy Structural studies and drug discovery of GPCRs

Key responsibilities: Lead a group to perform anti-cancer protein drugs development Cooperate with the overseas team to set up new labs Operation of the research center Apply for R&D funding Supervise the postgraduate studentsAchievement: Developing a recombinant anti-breast cancer TAT-PinX1 protein drug targeting telomeraseWe have generated a recombinant TAT-PinX1-C protein-containing TAT and C-terminal domain of PinX1 and examined the efficiency and mechanism of the protein in the suppression of breast cancer cell growth and tumorigenicity. Cell viability assays reveal that TAT-PinX1-C inhibits proliferation in a dose-dependent manner in all breast cell lines tested independent of their p53, ER, and HER2 status. The protein also inhibits colony formation of MDA-MB-231 cells in a dose-dependent manner. Annexin V and PI staining reveal that the protein promotes apoptosis of MDA-MB-231 cells. Cell cycle analysis indicates that the protein induces a G1 phase arrest. TRF Length measurement shows that the protein decreases the TRF Length of breast cancer cells. We will test the anti-tumor activity of the protein in xenograft nude mice next. These results suggest the potential of TAT-PinX1-C in targeted therapy of breast cancer.  Cooperated with the overseas team to set up three labs. Cooperated with the overseas team to achieve three important research funding. Published four research articles on Biophysical Chemistry, Protein Peptide Lett, etc.

Key responsibilities: Lead a Protein Production & Drug Screening Group Report to and communicate with client weekly Apply for R&D fundingAchievement: Purification and Crystallization of Human Telomerase. Seven hTERT fragments containing the RT domain were designed based on the sequence alignment and structure prediction. These constructs were overexpressed in E. Coli or HEK293 cells, and the fragments of hTERT (578-944) were purified at purity >90% and crystallized in two different conditions. Purification and Assay of 4 Kinases (cMET, Aurora B, PLK1, GSK3β). Purification and Assay Development of HDAC1. Purification and Drug Screening of Nuclear Receptors.  Development of HCV, HIV Diagnostic Reagents.

Study the mechanism and therapy of neurodegenerative diseases using a combination of solution and solid-state NMR, neutron and x-ray scattering and other physical methods.

Ph. D., Biochemistry And Molecular Biology

M.S., Environment Sciences

B.S., Pharmacy